PE Tech Report


Like this article?

Sign up to our free newsletter

DNA Script closes USD200m Series C financing

Script, a specialist in Enzymatic DNA Synthesis (EDS) for on-demand DNA printing, has completed its Series C financing, raising USD200 million of new capital. With this latest financing, DNA Script has raised USD315 million since the company was founded in 2014.

Accounts and funds advised by T Rowe Price Associates and Baillie Gifford participated in the second tranche of the Series C, along with Healthcor Management, eureKARE, and Irving Investors. They joined Coatue Management, Catalio Capital Management, Fidelity Management & Research Company LLC, Columbia Threadneedle Investments, Casdin Capital, as well as other investors who participated in the first closing.

Proceeds from this financing will be used to advance the SYNTAX Platform, DNA Script’s first commercial product powered by its proprietary EDS technology. SYNTAX empowers scientists to rapidly print synthetic nucleic acids for genomics and molecular biology applications at the convenience of their lab bench. On-demand printing enables labs to iterate without waiting days or weeks to receive their genetic material from third-party service providers.

Like this article? Sign up to our free newsletter